Rogério Gaspar

Rogério Gaspar is Professor of the Faculty of Pharmacy of the University of Lisbon (FFUL).


He is also the Director of the Institute for Interdisciplinary Research (3Is) of the University of Lisbon. Represents externally the University of Lisbon in several institutions of science, technology and entrepreneurship.


Until the beginning of his duties as Vice-Rector of the University of Lisbon (on July 25, 2013), he served as Deputy Director of the FFUL (since September 2012, with responsibility for research and international relations), in addition to being a member of the Scientific Council and Faculty Assembly. Between 2008 and 2013 he was also a member of the General Council of the University of Lisbon.


Graduated in Pharmaceutical Sciences (specialty of Industrial Pharmacy, July 1985), Doctorate in Pharmaceutical Sciences (Université Catholique de Louvain, June 1991), Aged in Pharmacy by the University of Coimbra (January 1999). His academic career was developed in the Universities of Coimbra (from 1985 to 2006), Católica de Louvaina (where he did doctorate between 1987 and 1991) and Lisbon (since February 8, 2006).


He was previously the coordinator of the Department of Galenic Pharmacy and Pharmaceutical Technology of the FFUL (between 2007 and 2013) and the research group "Nanomedicine & Drug Delivery Systems" (iMed.UL, 2007-2013). He also co-ordinated the IntraCell_ADD (Intracellular Trafficking Modulation for Advanced Drug Delivery) group at iMed.ULisboa in 2013 and 2014.


His primary area of ​​research is the development of nanometric-scale therapeutic systems (nanomedicines), and he has been responsible for coordinating projects with the pharmaceutical technology industry at various moments in his professional life. Currently his research is more focused on the oncology area and the modulation of the intracellular transport of pharmacologically active molecules including nucleic acids. At different times he integrated national and foreign research projects, including coordination functions. He has worked as a consultant in the pharmaceutical sector both at home and abroad (USA and Europe).


He held various positions as an expert and institutional officer (INFARMED and European Medicines Agency) in the area of ​​drug regulation, at national and European level, between 1995 and 2002 and between 2008 and 2011. These include Vice President INFARMED (1996-1999), Vice-President of the Board of Directors of INFARMED (2000-2002) and member of the Management Board of the European Medicines Agency (2000-2002).


He held the position of technical expert in the diplomatic field at REPER in Brussels for a number of years and coordinated the working group of the European Council responsible for the European Clinical Trials Directive (1999-2000). He participated as an expert or coordinator in international actions such as the initiation of the EU-Japan mutual recognition process in the area of ​​GMPs (2002), establishing the bases for a drug agency in Cape Verde (World Bank, 2002), training inspectors GMPs in ASEAN (2005 and 2006), "Look Forward Initiative in Nanomedicine" (European Science Foundation, 2002-2005), ESF Research Conferences in Nanomedicine (Barcelona, ​​2006, 2008 and 2010), ESF European Summer Schools in Nanomedicine (Cardiff - 2007, Lisbon -2009, Halle-Wurtenberg -2011), evaluation and launch of the "Centers of Excellence in Nanomedicine" of the ANDI-African Network for Drugs and Diagnostics Innovation (United Nations Economic Commission for Africa & African Union, 2011).


Between 2009 and 2013 he was a member of the Executive Committee of the European Federation of Pharmaceutical Sciences (EUFEPS) and served as Vice-President between 2011 and 2012 with the responsibility of coordinating the Science Policy.


He is a member of several Scientific Advisory Boards (SABs) at international level among which stand out CIBER-BBN (Spanish research network), EuroNanoMedNet-I and II (ERA-NET), TRANS-INT (FP7), NANOFAR European Nanomedicine). He has frequently been called to carry out national institutional evaluation functions, research institutes or doctoral program selection at the level of the European Union in Spain, Austria, Norway and South Africa. He is also a member of the Editorial / Advisory Board of several international scientific publications such as the International Journal of Nanomedicine (IF = 3,463 / Dove Medical Press), Nanomedicine: Nanotechnology, Biology and Medicine (IF = 6.930 / Elsevier) and Drug Delivery and Translational Research (Springer, begun in 2012).